158 related articles for article (PubMed ID: 38000171)
1. Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer.
Obaid G; Eroy M; Zhao J; Bano S; Mino-Kenudson M; Hasan T
J Photochem Photobiol B; 2024 Jan; 250():112811. PubMed ID: 38000171
[TBL] [Abstract][Full Text] [Related]
2. Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer.
Obaid G; Bano S; Thomsen H; Callaghan S; Shah N; Swain JWR; Jin W; Ding X; Cameron CG; McFarland SA; Wu J; Vangel M; Stoilova-McPhie S; Zhao J; Mino-Kenudson M; Lin C; Hasan T
Adv Sci (Weinh); 2022 Aug; 9(24):e2104594. PubMed ID: 35748165
[TBL] [Abstract][Full Text] [Related]
3. Impacting Pancreatic Cancer Therapy in Heterotypic
Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Immune Checkpoint Targeted Photoactivable Liposomes (iTPALs) Prime the Stroma of Pancreatic Tumors and Promote Self-Delivery.
Bhandari C; Moffat A; Shah N; Khan A; Quaye M; Fakhry J; Soma S; Nguyen A; Eroy M; Malkoochi A; Brekken R; Hasan T; Ferruzzi J; Obaid G
Adv Healthc Mater; 2024 Feb; ():e2304340. PubMed ID: 38324463
[TBL] [Abstract][Full Text] [Related]
5. Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids.
Saad MA; Zhung W; Stanley ME; Formica S; Grimaldo-Garcia S; Obaid G; Hasan T
Mol Pharm; 2022 Jul; 19(7):2549-2563. PubMed ID: 35583476
[TBL] [Abstract][Full Text] [Related]
6. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
7. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer.
Willumsen N; Ali SM; Leitzel K; Drabick JJ; Yee N; Polimera HV; Nagabhairu V; Krecko L; Ali A; Maddukuri A; Moku P; Ali A; Poulose J; Menon H; Pancholy N; Costa L; Karsdal MA; Lipton A
Sci Rep; 2019 Dec; 9(1):19761. PubMed ID: 31875000
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
9. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
10. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
11. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
13. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
[TBL] [Abstract][Full Text] [Related]
14. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
15. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
17. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.
Whatcott CJ; Diep CH; Jiang P; Watanabe A; LoBello J; Sima C; Hostetter G; Shepard HM; Von Hoff DD; Han H
Clin Cancer Res; 2015 Aug; 21(15):3561-8. PubMed ID: 25695692
[TBL] [Abstract][Full Text] [Related]
18. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
19. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.
Incio J; Liu H; Suboj P; Chin SM; Chen IX; Pinter M; Ng MR; Nia HT; Grahovac J; Kao S; Babykutty S; Huang Y; Jung K; Rahbari NN; Han X; Chauhan VP; Martin JD; Kahn J; Huang P; Desphande V; Michaelson J; Michelakos TP; Ferrone CR; Soares R; Boucher Y; Fukumura D; Jain RK
Cancer Discov; 2016 Aug; 6(8):852-69. PubMed ID: 27246539
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
